Abstract| Volume 23, ISSUE 10, SUPPLEMENT , S17, October 2017

Impact of Brain Natriuretic Peptide on Long-term Mortality in Acute Heart Failure Patients with Reduced, Mid-range and Preserved Ejection Fraction

      Introduction: Brain natriuretic peptide (BNP) is associated with mortality in acute heart failure (AHF) patients. However, it is unclear which BNP parameter; on admission, at discharge, or change during hospitalization, has the highest predictive performance for long-term mortality, and whether its prognostic impact differs according to new European HF phenotype classification by left ventricular ejection fraction (EF); HF with reduced EF (HFrEF), mid-range EF (HFmrEF), and preserved EF (HFpEF). Methods and Results: We examined 3026 consecutive AHF patients from our prospective registries. Prognostic performance of BNP was assessed by Harrell's C-index. During median follow-up of 677 days, 619 patients died. Discharge BNP had the highest C-index, 0.684, for mortality amongst all BNP parameters (P < .001), and was associated with all-cause mortality amongst in HFrEF, HFmrEF, and HFpEF patients with a significant interaction in multivariate Cox proportional hazard model [Hazard ratio (HR) 1.89, 95% confidence interval (CI) 1.53–2.33; HR 1.67, 95% CI 1.12–2.50; HR 1.45, 95% CI 1.13–1.87, respectively, P for interaction = 0.028]. Moreover, C-index of discharge BNP for all-cause mortality in HFrEF patients (0.723) was higher than that in HFmrEF patients (0.674) and HFpEF patients (0.653). Conclusion: In AHF patients, discharge BNP is more reliable marker than other BNP parameters for long-term outcome prediction, but its prognostic impact may be weakened in HFmrEF and HFpEF when compared with HFrEF.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect